drugset

drugset / Trial / NCT00742833

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

NCT00742833 ↗

Phase 2 Completed 400 enrolled Kissei Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ritobegron	Small molecule	—	—

Indications